MNKD MannKind Corporation - Common Stock
NASDAQ · Biotechnology · SEC EDGAR에서 보기 ↗ 종가 10월 2, 2026 10-K/10-Q 8월 5, 2026
$3.80
· 52주 범위 %
· 저점 이상
· 고점까지
$2.2352주 저점
$6.5152주 고점
시가총액 (MRQ)
$1.18B
P/E (TTM)
-29.2
EPS (TTM)
$-0.13
매출 (TTM)
$394M
내 배지
52주 범위
$2–$7
애널리스트 평점
BUY
목표 주가
$8
P/E
-29.2
ROE
71.4%
순이익률
-11.1%
배지 스트립이 비어 있습니다. 이 페이지의 아무 지표나 고정하세요.
MNKD 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$3.80
시가총액 (MRQ)
$1.18B
P/E (TTM)
-29.2
EPS (TTM)
$-0.13
매출 (TTM)
$394M
ROE (TTM)
71.4%
52주 범위
$2–$7
MNKD 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
범위
막대
막대 세분성은 선택한 기간에 따라 조정됩니다. 막대의 시가/고가/저가/종가를 보려면 차트에 마우스를 올리세요.
주식 분할
| 배당락일 | 분할 | 유형 |
|---|---|---|
| 2017년 3월 3일 | 1-for-5 | 역방향 |
MannKind Corporation - Common Stock 정보 위키백과 회사 개요
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
MannKind Corporation was named after its founder, Alfred E. Mann.
History
Founded in February 1991, the company's present form is a result of a 2003 merger of three companies owned by Alfred E. Mann: Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing an allergy vaccine technology. Pharmaceutical Discovery was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).
The FDA approved Afrezza on June 27, 2014.
On August 11, 2014 MannKind entered into an exclusive global licensing agreement with Sanofi for Afrezza sales. Under the agreement, MannKind received $150 million cash from Sanofi, in exchange for sharing profits and losses of sales of Afrezza, with 65% for Sanofi and 35% for MannKind. On January 5, 2016, MannKind Corporation announced the termination of the license and collaboration agreement with Sanofi. By December 2017, the company had lost 11% of its trading volume due to the poor sales.
In March 2020, the company announced it was working with fellow pharmaceutical company Immix Biopharma to try to develop an inhalable treatment for acute respiratory distress syndrome, a lung disease.
Products and product candidates
The firm has developed Afrezza a rapid-acting insulin peaking 12 to 15 minutes after inhalation and exiting the body within 2–3 hours. The inhalation technology uses a miniature, breath-powered inhaler in combination with single-use cartridges containing pre-metered doses. Initial pharmacokinetic studies were followed by studies of safety and efficiency involving Technosphere formulations of different therapeutic proteins.
Leadership
Mann was chief executive officer until January 12, 2015 when Hakan Edstrom became CEO and Mann transitioned to executive chairman.
In November 2015, Hakan Edstrom stepped down as CEO and president. Company founder Alfred Mann stepped in as interim CEO on November 19, 2015. In 2016, Matthew Pfeffer was appointed CEO of MannKind, and served as both CEO and CFO. In May 2017, Michael Castagna was named CEO of the company.
Facilities
MannKind has a large corporate office in Westlake Village, California. The Afrezza manufacturing facility is in Danbury, Connecticut. In 2022, the company moved its official headquarters to Danbury.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
섹터Healthcare
산업Biotechnology
직원591
국가US
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출$349M2016-12-31 → 2025-12-31
EPS$0.022016-12-31 → 2025-12-31
잉여현금흐름$14M2018-12-31 → 2025-12-31
순이익률-11.1%2017-12-31 → 2025-12-31
가치 평가 및 비율
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
| 지표 | 5년 추세 | MNKD | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| P/E (TTM) | -29.25년 평균 ≈45.5 | ≈45.5 | · | · | |
| P/S (TTM) | 3.05년 평균 ≈9.1 | ≈9.1 | 21.2 | 저평가 | |
| P/B (MRQ) | -17.55년 평균 ≈-14.7 | ≈-14.7 | · | · | |
| 주가 / FCF (TTM) | -64.95년 평균 ≈7.7 | ≈7.7 | · | · | |
| 주가 / 현금 흐름 (TTM) | -146.25년 평균 ≈27.0 | ≈27.0 | · | · | |
| 주가 / 유형 장부 가치 (MRQ) | -16.3 | · | · | · |
동종 기업 중앙값은 지표별로 표준화된 기준으로 계산되며, 이 주식에 표시된 TTM/MRQ 기준과 항상 일치하지 않을 수 있습니다.
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
| 지표 | 5년 추세 | MNKD | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| 영업이익률 (TTM) | 2.3%5년 평균 ≈-17.1% | ≈-17.1% | -308.7% | 최상위권 | |
| EBITDA Margin (EBITDA 마진) | 11.1%5년 평균 ≈-17.1% | ≈-17.1% | -308.7% | 최상위권 | |
| 세전 마진 (TTM) | -12.4%5년 평균 ≈-37.8% | ≈-37.8% | · | · | |
| 순이익률 (TTM) | -11.1%5년 평균 ≈-37.9% | ≈-37.9% | -214.0% | 최상위권 | |
| ROA (TTM) | -7.6%5년 평균 ≈-12.4% | ≈-12.4% | -44.4% | 최상위권 | |
| ROE (TTM) | 71.4%5년 평균 ≈10.3% | ≈10.3% | -11.7% | 동일 | |
| ROIC | -316.9%5년 평균 ≈-71.2% | ≈-71.2% | -128.0% | 약함 |
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
| 지표 | 5년 추세 | MNKD | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| 유동비율 (MRQ) | 1.75년 평균 ≈3.3 | ≈3.3 | 10.6 | 낮은 유동성 | |
| 당좌 비율 (MRQ) | 1.15년 평균 ≈2.8 | ≈2.8 | 5.1 | 낮은 유동성 |
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
| 지표 | 5년 추세 | MNKD | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| Revenue YoY (매출 YoY) | 22.2%5년 평균 ≈42.6% | ≈42.6% | · | · | |
| Revenue CAGR 3Y (매출 CAGR 3년) | 51.8%5년 평균 ≈50.9% | ≈50.9% | · | · | |
| Revenue CAGR 5Y (매출 CAGR 5년) | 39.9% | · | · | · | |
| EPS YoY | -80.0% | · | · | · | |
| Net Income YoY (순이익 YoY) | -78.8% | · | · | · |
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
| 지표 | 5년 추세 | MNKD | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| Asset Turnover (자산 회전율) | 0.65년 평균 ≈0.5 | ≈0.5 | 0.3 | 최상위권 | |
| Inventory Turnover (재고 회전율) | 0.85년 평균 ≈1.2 | ≈1.2 | · | · | |
| Receivables Turnover (매출 채권 회전율) | 13.95년 평균 ≈14.7 | ≈14.7 | · | · | |
| Revenue / Employee (연간 매출액 ÷ 직원 수(yfinance 보고 인원수). 파생 — 저장된 SEC-XBRL 개념이 아님.) | ≈$590.5K | · | · | · |
가치 · ≈ 5년 평균 · 산업 중앙값 · 중앙값 대비 평가
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
-86.3%
다음 실적
11월 03, 2026
| 기간 | 보고서 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|---|
| 2026년 6월 30일 | 8월 12, 2026 | $-0.06 | $-0.00 | — |
| 2026년 3월 31일 | 5월 13, 2026 | $-0.05 | $-0.00 | — |
| 2025년 12월 31일 | $-0.05 | $0.01 | -440.1% | |
| 2025년 9월 30일 | $0.07 | $0.02 | 205.9% | |
| 2025년 6월 30일 | $0.00 | $0.05 | -100.0% | |
| 2025년 3월 31일 | $0.04 | $0.04 | -10.9% |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $349M | $286M | $199M | $100M | $75M | $65M | $63M | $28M | $12M | $175M | $0 | $0 | |
| Cost of Revenue | $27M | $17M | $21M | $16M | $17M | $15M | $20M | $19M | $17M | $17M | $65M | · | |
| SG&A Expense | $144M | $94M | $94M | $91M | $32M | $25M | $75M | $80M | $75M | $47M | $41M | $79M | |
| Operating Expenses | $88M | $77M | $63M | $57M | $39M | $25M | $108M | $104M | $120M | $107M | $345M | $180M | |
| Operating Income | $39M | $73M | $9M | $-64M | $-47M | $-48M | $-45M | $-77M | $-108M | $67M | $-345M | $-180M | |
| Interest Expense | · | · | $15M | $15M | $15M | · | · | · | · | · | $24M | $20M | |
| Interest Income | $8M | $13M | $6M | $3M | $112.0K | $167.0K | $997.0K | $501.0K | $293.0K | $85.0K | $18.0K | $9.0K | |
| Other Non-op | $-1M | $32.0K | $122.0K | $-102.0K | $-239.0K | $23.0K | $-926.0K | $-437.0K | $13.0K | $-597.0K | $1M | $2M | |
| Pretax Income | $1M | $31M | $-10M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| Income Tax | $-4M | $3M | $2M | $0 | $0 | $-218.0K | $0 | $240.0K | $51.0K | $0 | $0 | $0 | |
| Net Income | $6M | $28M | $-12M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| EPS (Basic) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | · | $-0.60 | $-1.13 | $1.37 | $-4.54 | $-2.57 | |
| EPS (Diluted) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | · | $-0.60 | $-1.13 | $1.36 | $-4.54 | $-2.57 | |
| Shares (Basic) | 305,639,000 | 274,415,000 | 267,014,000 | 257,092,000 | 249,244,000 | 222,585,000 | · | 144,136,000 | 104,245,000 | 92,053,000 | 81,233,000 | 77,045,000 | |
| Shares (Diluted) | 314,112,000 | 283,844,000 | 267,014,000 | 257,092,000 | 249,244,000 | 222,585,000 | · | 144,136,000 | 104,245,000 | 92,085,000 | 81,233,000 | 77,045,000 | |
| EBITDA | $39M | $73M | $9M | $-64M | $-47M | $-48M | $-45M | $-77M | $-106M | · | $-334M | $-170M |
대차대조표
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $75M | $46M | $238M | $70M | $124M | $67M | $30M | $71M | $44M | $23M | $59M | $121M | |
| Short-term Investments | $96M | $151M | $57M | $101M | $80M | $0 | $20M | · | · | · | · | · | |
| Receivables | $38M | $12M | $15M | $17M | $5M | $4M | $4M | $4M | $3M | $302.0K | $23.0K | $50M | |
| Inventory | $35M | $28M | $29M | $22M | $7M | $5M | $4M | $4M | $3M | $2M | · | $10M | |
| Prepaid Expense | $47M | $31M | $35M | $25M | $3M | $3M | $3M | $3M | $3M | $4M | $4M | $20M | |
| Current Assets | $292M | $268M | $373M | $235M | $219M | $79M | $61M | $82M | $57M | $77M | $77M | $201M | |
| PP&E (Net) | $82M | $85M | $84M | $45M | $37M | $26M | $27M | $26M | $27M | $29M | $49M | $192M | |
| PP&E (Gross) | $196M | $192M | $186M | $144M | $134M | $123M | $122M | $126M | $128M | $129M | $168M | $310M | |
| Accum. Depreciation | $114M | $107M | $102M | $99M | $98M | $97M | $95M | $100M | $101M | $100M | $120M | $118M | |
| Goodwill | $68M | $2M | $2M | $2M | · | · | · | · | · | · | · | · | |
| Intangibles | $5M | $5M | $1M | $1M | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $27M | $7M | $10M | $8M | $3M | $6M | $249.0K | $437.0K | $648.0K | $1M | $848.0K | |
| Total Assets | $792M | $394M | $475M | $295M | $321M | $109M | $94M | $108M | $85M | $107M | $126M | $394M | |
| Accounts Payable | $9M | $7M | $10M | $11M | $7M | $6M | $5M | $5M | $7M | $3M | $16M | $7M | |
| Accrued Liabilities | $65M | $40M | $42M | $36M | $27M | $20M | $16M | $15M | $12M | $8M | $8M | $26M | |
| Short-term Debt | · | · | · | · | · | · | $5M | · | · | · | · | · | |
| Current Liabilities | $171M | $82M | $104M | $67M | $48M | $74M | $66M | $75M | $88M | $92M | $268M | $403M | |
| Capital Leases | $11M | $12M | $4M | $5M | $1M | $1M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | $5M | · | · | · | · | · | $15M | $12M | |
| Total Liabilities | $843M | $473M | $721M | $546M | $531M | $289M | $284M | $283M | $299M | $291M | $477M | $468M | |
| Long-term Debt | $355M | $36M | $269M | $273M | $281M | $122M | $119M | $102M | $157M | · | · | · | |
| Total Debt | · | · | · | · | · | · | $5M | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $957.0K | $4M | $4M | |
| Retained Earnings | $-3.20B | $-3.20B | $-3.23B | $-3.22B | $-3.13B | $-3.05B | $-2.99B | $-2.94B | $-2.85B | $-2.74B | $-2.86B | $-2.49B | |
| AOCI | $115.0K | $1M | · | · | · | · | $-19.0K | $-19.0K | $-18.0K | $-24.0K | $-20.0K | $-14.0K | |
| Stockholders' Equity | $-51M | $-79M | $-246M | $-251M | $-209M | $-180M | $-191M | $-175M | $-215M | $-184M | $-350M | $-74M | |
| Liabilities + Equity | $792M | $394M | $475M | $295M | $321M | $109M | $94M | $108M | $85M | $107M | $126M | $394M | |
| Shares Outstanding | 307,832,587 | 302,959,782 | 270,034,495 | 263,793,305 | 251,477,562 | 242,117,089 | 211,787,573 | 187,029,967 | 119,053,414 | 95,680,831 | 85,734,188 | 406,059,089 |
현금 흐름
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $12M | $7M | $5M | $3M | $2M | $2M | $972.0K | $3M | $2M | $2M | $11M | $10M | |
| Stock-based Comp | $24M | $21M | $18M | $13M | $12M | $7M | $6M | $7M | $5M | $5M | $9M | $49M | |
| Deferred Tax | $-19M | $4M | $7M | $-10M | $-20M | $-5M | $-5M | $-11M | $-260M | $48M | $-80M | $-66M | |
| Amort. of Intangibles | $4M | · | · | · | · | · | · | · | · | · | · | · | |
| Restructuring | · | · | · | · | · | · | · | · | · | $2M | $6M | $2M | |
| Other Non-cash | · | · | · | · | · | · | · | · | $306M | · | $291M | $144M | |
| Operating Cash Flow | $18M | $43M | $34M | $-81M | $-62M | $-28M | $-88M | $-38M | $-65M | $-78M | $-57M | $4M | |
| CapEx | $5M | $10M | $42M | $8M | $11M | $801.0K | $3M | $354.0K | · | $1M | $10M | $24M | |
| Investing Cash Flow | $-305M | $-97M | $-2M | $5M | $-152M | $15M | $-23M | $-234.0K | $17M | $-1M | · | · | |
| Debt Issued | · | · | · | · | · | $5M | · | · | · | · | · | $20M | |
| Net Debt Issued | · | · | · | · | · | $5M | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | $564.0K | $893.0K | $28M | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | $564.0K | · | $28M | · | |
| Financing Cash Flow | $315M | $-137M | $137M | $21M | $270M | $50M | $70M | $61M | $74M | $43M | · | · | |
| Net Change in Cash | $29M | $-191M | $169M | $-54M | $57M | $37M | $-41M | $23M | $25M | $-36M | $-62M | $50M | |
| Taxes Paid | $2M | $4M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $14M | $33M | $-8M | $-88M | $-73M | $-29M | $-91M | $-38M | · | · | $-68M | $-20M | |
| Levered FCF | · | · | $-26M | $-98M | · | · | · | · | · | · | $-92M | · |
수익성
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% | -73.6% | -70.8% | -274.9% | -921.1% | · | · | · | |
| Net Margin | 1.7% | 9.7% | -6.0% | -87.6% | -107.3% | -87.9% | -82.3% | -312.2% | -999.0% | · | · | · | |
| Pretax Margin | 0.40% | 10.7% | -5.2% | -87.6% | -107.3% | -88.2% | -82.3% | -311.3% | -998.6% | · | · | · | |
| EBITDA Margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% | -73.6% | -70.8% | -274.9% | -905.8% | · | · | · | |
| ROA | 0.99% | 6.3% | -3.1% | -28.4% | -37.7% | -56.6% | -51.5% | -90.5% | -122.4% | · | -141.5% | -60.8% | |
| ROE | -11.1% | -19.1% | 4.8% | 35.8% | 41.1% | 31.2% | 27.7% | 45.7% | 58.9% | · | 173.8% | 379.7% | |
| ROIC | -316.9% | -83.2% | -4.1% | 25.6% | 22.5% | 26.5% | 24.0% | 43.9% | 50.4% | · | 98.4% | · |
유동성 및 지급능력
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | 3.3 | 3.6 | 3.5 | 4.5 | 1.1 | 0.9 | 1.1 | 0.7 | · | 0.3 | 0.5 | |
| Quick Ratio | 1.2 | 2.6 | 3.0 | 2.8 | 4.3 | 1.0 | 0.8 | 1.0 | 0.5 | · | 0.2 | 0.4 | |
| Debt / Equity | · | · | · | · | · | · | -0.0 | · | · | · | · | · | |
| Interest Coverage | · | · | 0.6 | -6.7 | · | · | · | · | · | · | -14.3 | -8.8 |
효율성
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.7 | 0.5 | 0.3 | 0.4 | 0.6 | 0.6 | 0.3 | 0.1 | · | 0.0 | · | |
| Inventory Turnover | 0.8 | 0.6 | 0.8 | 1.1 | 2.8 | 3.3 | 5.2 | 6.2 | 6.9 | · | · | · | |
| Receivables Turnover | 13.9 | 21.4 | 12.6 | 9.3 | 16.4 | 16.9 | 16.7 | 8.2 | 7.6 | · | 0.0 | · |
주당
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.17 | $-0.26 | $-0.91 | $-0.95 | $-0.83 | $-0.75 | $-0.90 | $-0.94 | $-1.80 | · | $-0.82 | $-0.18 | |
| Revenue / Share | $1.11 | $1.01 | $0.75 | $0.39 | · | · | · | $0.19 | $0.11 | · | · | · | |
| Cash Flow / Share | $0.06 | $0.15 | $0.13 | $-0.31 | · | · | · | $-0.26 | $-0.62 | · | · | · | |
| Cash / Share | $0.24 | $0.15 | $0.88 | $0.26 | $0.49 | $0.28 | $0.14 | $0.38 | $0.37 | · | $0.14 | $0.30 | |
| EPS (TTM) | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 | $-0.26 | $-0.63 | $-0.60 | $-1.13 | $1.36 | $-4.54 | $-2.57 |
성장률
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 22.2% | 43.5% | 99.4% | 32.2% | 15.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 51.8% | 55.8% | 45.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 39.9% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -80.0% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -78.8% | · | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM)
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $349M | $286M | $199M | $100M | $75M | $65M | $63M | $28M | $12M | $175M | $0 | $0 | |
| Net Income TTM | $6M | $28M | $-12M | $-87M | $-81M | $-57M | $-52M | $-87M | $-117M | $126M | $-368M | $-198M | |
| Market Cap | $1.75B | $1.95B | $983M | $1.39B | $1.10B | $758M | $273M | $198M | $276M | · | $3.11B | $10.60B | |
| Enterprise Value | · | · | · | · | · | · | $228M | · | · | · | · | · | |
| P/E | 283.5 | 64.3 | -91.0 | -15.5 | -13.7 | -12.0 | -2.0 | -1.8 | -2.1 | 2.4 | -1.6 | -10.2 | |
| P/S | 5.0 | 6.8 | 4.9 | 13.9 | 14.6 | 11.6 | 4.3 | 7.1 | 23.5 | · | · | · | |
| P/B | -34.2 | -24.7 | -4.0 | -5.5 | -5.2 | -4.2 | -1.4 | -1.1 | -1.3 | · | -8.9 | -143.7 | |
| P / Cash Flow | 95.6 | 45.8 | 28.8 | -17.2 | -17.8 | -26.9 | -3.1 | -5.3 | -4.3 | · | -54.3 | 2593.8 | |
| P / FCF | 127.5 | 59.4 | -117.8 | -15.7 | -15.0 | -26.2 | -3.0 | -5.2 | · | · | -46.0 | -529.6 | |
| EV / EBITDA | · | · | · | · | · | · | -5.1 | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | · | -2.5 | · | · | · | · | · | |
| EV / Revenue | · | · | · | · | · | · | 3.6 | · | · | · | · | · | |
| Earnings Yield | 0.35% | 1.6% | -1.1% | -6.5% | -7.3% | -8.3% | -48.8% | -56.6% | -48.7% | 42.5% | -62.6% | -9.8% |
손익계산서
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109M | $90M | $112M | $82M | $77M | $78M | $77M | $70M | $72M | $66M | $58M | $51M | $49M | $41M | $36M | $33M | |
| Cost of Revenue | $14M | $8M | $14M | $4M | $5M | $4M | $5M | $3M | $6M | $4M | $6M | $4M | $5M | $6M | $4M | $5M | |
| SG&A Expense | $58M | $54M | $58M | $29M | $32M | $25M | $24M | $24M | $24M | $22M | $61M | $11M | $12M | $11M | $64M | $9M | |
| Operating Expenses | $30M | $92M | $-103M | $63M | $21M | $56M | $-86M | $57M | $56M | $50M | $18M | $14M | $14M | $16M | $16M | $17M | |
| Operating Income | $-350.0K | $-2M | $-8M | $19M | $5M | $22M | $26M | $13M | $17M | $17M | $8M | $5M | $2M | $-6M | $-13M | $-10M | |
| Interest Expense | · | · | · | · | · | · | · | · | $6M | $3M | · | $3M | $7M | $3M | · | $3M | |
| Interest Income | $1M | $1M | $2M | $3M | $2M | $2M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $957.0K | $663.0K | |
| Other Non-op | $-5M | $-3M | $23M | $-11M | $-4M | $-9M | $24M | $110.0K | $-18M | $-6M | $-164.0K | $318.0K | $-143.0K | $111.0K | $105.0K | $-207.0K | |
| Pretax Income | $-19M | $-16M | $-21M | $8M | $940.0K | $14M | $8M | $13M | $-2M | $11M | $3M | $2M | $-5M | $-10M | $-18M | $-14M | |
| Income Tax | $-106.0K | $253.0K | $-5M | $-204.0K | $272.0K | $459.0K | $1M | $1M | $323.0K | $264.0K | $2M | $0 | $0 | $0 | · | $0 | |
| Net Income | $-19M | $-17M | $-16M | $8M | $668.0K | $13M | $7M | $12M | $-2M | $11M | $1M | $2M | $-5M | $-10M | $-18M | $-14M | |
| EPS (Basic) | $-0.06 | $-0.05 | $-0.05 | $0.03 | $0.00 | $0.04 | $0.03 | $0.04 | $-0.01 | $0.04 | $0.01 | $0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.06 | |
| EPS (Diluted) | $-0.06 | $-0.05 | $-0.05 | $0.03 | $0.00 | $0.04 | $0.03 | $0.04 | $-0.01 | $0.04 | $0.01 | $0.01 | $-0.02 | $-0.04 | $-0.07 | $-0.06 | |
| Shares (Basic) | 309,191,000 | 308,267,000 | · | 306,806,000 | 304,954,000 | 303,481,000 | · | 274,998,000 | 273,056,000 | 270,356,000 | · | 268,732,000 | 265,626,000 | 263,969,000 | · | 259,300,000 | |
| Shares (Diluted) | 309,191,000 | 308,267,000 | · | 311,638,000 | 311,484,000 | 320,897,000 | · | 284,693,000 | 273,056,000 | 324,733,000 | · | 323,770,000 | 265,626,000 | 263,969,000 | · | 259,300,000 | |
| EBITDA | · | $-2M | · | $19M | $5M | $22M | · | $13M | $17M | $17M | · | $5M | $2M | $-6M | · | $-10M |
대차대조표
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53M | $53M | $75M | $127M | $57M | $47M | $46M | $62M | $97M | $193M | · | $83M | $86M | $86M | · | $54M | |
| Short-term Investments | $58M | $81M | $96M | $133M | $122M | $134M | $151M | $189M | $151M | $107M | · | $58M | $58M | $80M | · | $111M | |
| Receivables | $43M | $28M | $38M | $17M | $27M | $29M | $12M | $18M | $23M | $20M | · | $22M | $28M | $20M | · | $23M | |
| Inventory | $44M | $49M | $35M | $27M | $28M | $29M | $28M | $27M | $25M | $26M | · | $27M | $25M | $22M | · | $18M | |
| Prepaid Expense | $47M | $40M | $47M | $54M | $44M | $34M | $31M | $31M | $30M | $36M | · | $36M | $33M | $15M | · | $12M | |
| Current Assets | $246M | $251M | $292M | $359M | $279M | $274M | $268M | $328M | $326M | $383M | · | $226M | $230M | $223M | · | $218M | |
| PP&E (Net) | $85M | $83M | $82M | $83M | $83M | $84M | $85M | $85M | $85M | $84M | · | $80M | $70M | $55M | · | $41M | |
| PP&E (Gross) | $203M | $198M | $196M | $195M | $194M | $192M | $192M | $192M | $190M | $186M | · | $182M | $170M | $154M | · | $140M | |
| Accum. Depreciation | $118M | $116M | $114M | $113M | $111M | $109M | $107M | $107M | $105M | $103M | · | $101M | $100M | $100M | · | $99M | |
| Goodwill | $68M | $68M | $68M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $3M | |
| Intangibles | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-current Assets | $17M | $22M | $20M | $19M | $20M | $28M | $27M | $26M | $16M | $7M | · | $8M | $8M | $16M | · | $17M | |
| Total Assets | $732M | $744M | $792M | $495M | $412M | $410M | $394M | $464M | $444M | $481M | · | $320M | $313M | $298M | · | $294M | |
| Accounts Payable | $11M | $16M | $9M | $7M | $10M | $5M | $7M | $6M | $10M | $7M | · | $17M | $17M | $14M | · | $10M | |
| Accrued Liabilities | $61M | $59M | $65M | $31M | $31M | $40M | $40M | $37M | $41M | $42M | · | $32M | $37M | $33M | · | $30M | |
| Current Liabilities | $143M | $135M | $171M | $109M | $112M | $116M | $82M | $72M | $80M | $100M | · | $96M | $97M | $82M | · | $60M | |
| Capital Leases | $10M | $10M | $11M | $10M | $11M | $11M | $12M | $12M | $3M | $4M | · | $4M | $5M | $5M | · | $6M | |
| Total Liabilities | $800M | $804M | $843M | $539M | $467M | $469M | $473M | $674M | $670M | $711M | · | $572M | $574M | $554M | · | $532M | |
| Long-term Debt | $319M | $319M | $355M | $110M | $36M | $36M | $36M | $228M | $228M | $264M | · | $273M | $274M | $274M | · | $273M | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $3M | $3M | $3M | · | $3M | |
| Retained Earnings | $-3.23B | $-3.21B | $-3.20B | $-3.18B | $-3.19B | $-3.19B | $-3.20B | $-3.21B | $-3.22B | $-3.22B | · | $-3.23B | $-3.23B | $-3.23B | · | $-3.20B | |
| AOCI | $-19.0K | $-4.0K | $115.0K | $137.0K | $1M | $1M | $1M | $588.0K | · | · | · | $443.0K | $443.0K | · | · | $-1M | |
| Stockholders' Equity | $-67M | $-59M | $-51M | $-45M | $-55M | $-59M | $-79M | $-210M | $-226M | $-230M | $-246M | $-252M | $-260M | $-255M | $-251M | $-238M | |
| Liabilities + Equity | $732M | $744M | $792M | $495M | $412M | $410M | $394M | $464M | $444M | $481M | · | $320M | $313M | $298M | · | $294M | |
| Shares Outstanding | 309,911,682 | 308,907,331 | 307,832,587 | 307,027,189 | 306,332,133 | 303,918,969 | 302,959,782 | 275,775,038 | 274,467,247 | 270,801,781 | · | 269,543,539 | 268,235,145 | 264,278,760 | · | 263,156,165 |
현금 흐름
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $6M | $6M | $6M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $-427.0K | |
| Stock-based Comp | $10M | $6M | $7M | $4M | $8M | $5M | $6M | $5M | $6M | $4M | $4M | $5M | $6M | $4M | $3M | $4M | |
| Amort. of Intangibles | $4M | $4M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-18M | $-5M | $-8M | $24M | $9M | $-6M | $23M | $9M | $4M | $7M | $22M | $9M | $3M | $1M | $-2M | $-28M | |
| CapEx | $5M | $2M | $2M | $1M | $1M | $330.0K | $3M | $1M | $3M | $2M | $6M | $11M | $17M | $8M | $5M | $271.0K | |
| Investing Cash Flow | $18M | $19M | $-292M | $-25M | $6M | $6M | $48M | $-41M | $-55M | $-48M | $-8M | $-12M | $4M | $14M | $15M | $27M | |
| Financing Cash Flow | $559.0K | $-35M | $247M | $72M | $-6M | $1M | $-87M | $-2M | $-45M | $-3M | $142M | $-283.0K | $-6M | $1M | $3M | $20M | |
| Net Change in Cash | $97.0K | $-22M | $-53M | $70M | $10M | $975.0K | $-16M | $-34M | $-96M | $-45M | $155M | $-3M | $315.0K | $16M | $15M | $19M | |
| Taxes Paid | $753.0K | $63.0K | $549.0K | $80.0K | $869.0K | $207.0K | $2M | $236.0K | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-7M | · | · | · | $-7M | · | · | · | $4M | · | · | · | $-7M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $2M | · | · | · | $-10M | · | · |
수익성
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | -1.8% | · | 23.0% | 6.9% | 28.4% | · | 18.2% | 22.9% | 25.2% | · | 9.9% | 3.5% | -14.8% | · | -29.3% | |
| Net Margin | · | -18.4% | · | 9.7% | 0.87% | 16.8% | · | 16.5% | -2.8% | 16.0% | · | 3.4% | -10.8% | -24.1% | · | -44.0% | |
| Pretax Margin | · | -18.1% | · | 9.5% | 1.2% | 17.4% | · | 18.4% | -2.3% | 16.4% | · | 3.4% | -10.8% | -24.1% | · | -44.0% | |
| EBITDA Margin | · | -1.8% | · | 23.0% | 6.9% | 28.4% | · | 18.2% | 22.9% | 25.2% | · | 9.9% | 3.5% | -14.8% | · | -29.3% | |
| ROA | · | -2.9% | · | 1.7% | 0.16% | 2.9% | · | 2.9% | -0.53% | 2.7% | · | 0.56% | -1.8% | -3.2% | · | -5.4% | |
| ROE | · | 28.2% | · | -6.3% | -0.48% | -9.1% | · | -5.0% | 0.83% | -4.4% | · | -0.70% | 2.1% | 4.0% | · | 6.8% | |
| ROIC | · | 2.9% | · | -43.5% | -6.8% | -36.8% | · | -5.5% | -8.8% | -7.1% | · | -2.0% | -0.66% | 2.4% | · | · |
유동성 및 지급능력
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 1.9 | · | 3.3 | 2.5 | 2.4 | · | 4.5 | 4.1 | 3.8 | · | 2.3 | 2.4 | 2.7 | · | 3.7 | |
| Quick Ratio | · | 1.2 | · | 2.5 | 1.8 | 1.8 | · | 3.7 | 3.4 | 3.2 | · | 1.7 | 1.8 | 2.3 | · | 3.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 2.7 | 6.5 | · | 1.8 | 0.3 | -2.5 | · | · |
효율성
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | · | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.4 | · | 0.4 | |
| Receivables Turnover | · | 3.2 | · | 4.6 | 3.0 | 3.2 | · | 3.5 | 2.8 | 3.3 | · | 2.3 | 2.3 | 2.8 | · | 2.0 |
주당
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | · | $-0.19 | · | $-0.15 | $-0.18 | $-0.19 | · | $-0.76 | $-0.82 | $-0.85 | · | $-0.93 | $-0.97 | $-0.97 | · | $-0.90 | |
| Revenue / Share | · | $0.29 | · | $0.26 | $0.25 | $0.24 | · | $0.25 | $0.27 | $0.20 | · | $0.16 | $0.18 | $0.15 | · | $0.13 | |
| Cash Flow / Share | · | $-0.02 | · | · | · | $-0.02 | · | · | · | $0.02 | · | · | · | $0.00 | · | · | |
| Cash / Share | · | $0.17 | · | $0.41 | $0.19 | $0.16 | · | $0.23 | $0.35 | $0.71 | · | $0.31 | $0.32 | $0.32 | · | $0.21 | |
| EPS (TTM) | $-0.08 | $-0.07 | · | $0.10 | $0.11 | $0.10 | · | $0.08 | $0.05 | $0.04 | · | $-0.12 | $-0.19 | $-0.28 | · | $-0.38 |
가치 평가 (TTM)
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $358M | $361M | · | $314M | $302M | $298M | · | $267M | $248M | $225M | · | $177M | $158M | $128M | · | $76M | |
| Net Income TTM | $-27M | $-24M | · | $29M | $33M | $30M | · | $22M | $12M | $8M | · | $-31M | $-47M | $-71M | · | $-98M | |
| Market Cap | · | $757M | · | $1.65B | $1.15B | $1.53B | · | $1.73B | $1.43B | $1.23B | · | $1.11B | $1.09B | $1.08B | · | $813M | |
| P/E | -53.2 | -35.0 | · | 53.7 | 34.0 | 50.3 | · | 78.6 | 104.4 | 113.2 | · | -34.4 | -21.4 | -14.6 | · | -8.1 | |
| P/S | · | 2.1 | · | 5.3 | 3.8 | 5.1 | · | 6.5 | 5.8 | 5.5 | · | 6.3 | 6.9 | 8.4 | · | 10.7 | |
| P/B | · | -12.8 | · | -37.0 | -20.8 | -26.1 | · | -8.3 | -6.3 | -5.3 | · | -4.4 | -4.2 | -4.2 | · | -3.4 | |
| P / Cash Flow | · | -141.1 | · | · | · | -239.7 | · | · | · | 183.0 | · | · | · | 937.3 | · | · | |
| Earnings Yield | -1.9% | -2.9% | · | 1.9% | 2.9% | 2.0% | · | 1.3% | 0.96% | 0.88% | · | -2.9% | -4.7% | -6.8% | · | -12.3% |
최신 기간은 왼쪽에 · null 값은 ·로 표시
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 매출 | $349M | $286M | $199M | $100M | $75M |
| 영업이익률 % | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% |
| 순이익 | $6M | $28M | $-12M | $-87M | $-81M |
| 희석 EPS | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 |
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 유동비율 | 1.7 | 3.3 | 3.6 | 3.5 | 4.5 |
| 당좌 비율 | 1.2 | 2.6 | 3.0 | 2.8 | 4.3 |
| 지표 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 잉여현금흐름 | $14M | $33M | $-8M | $-88M | $-73M |
기관 투자자 (13F) 271개의 제출자 · $883.4M 전체 · 기준일 2026년 9월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
보유자
271
보유 가치
$883.4M
신규 포지션
51
청산 포지션
39
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 51 (0 이전 분기 대비) | 39 (-8 이전 분기 대비) | 98 (+12 이전 분기 대비) | 63 (-7 이전 분기 대비) | +1.9M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| BlackRock, Inc. | $136,887,530 | 32,133,223 | 15.50% | 주식 |
| VANGUARD GROUP INC | $101,384,549 | 17,880,873 | 11.48% | 주식 |
| Rubric Capital Management LP | $76,680,000 | 18,000,000 | 8.68% | 주식 |
| STATE STREET CORP | $68,901,423 | 16,174,043 | 7.80% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $56,101,610 | 13,169,392 | 6.35% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $33,861,886 | 7,947,203 | 3.83% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $33,418,878 | 7,844,807 | 3.78% | 주식 |
| Frazier Life Sciences Management, L.P. | $28,116,000 | 6,600,000 | 3.18% | 주식 |
| Deep Track Capital, LP | $25,560,000 | 6,000,000 | 2.89% | 주식 |
| 180 WEALTH ADVISORS, LLC | $21,126,835 | 4,959,351 | 2.39% | 주식 |
| FMR LLC | $17,470,455 | 4,101,046 | 1.98% | 주식 |
| TSP Capital Management Group, LLC | $16,923,596 | 3,972,675 | 1.92% | 주식 |
| AQR CAPITAL MANAGEMENT LLC | $16,225,589 | 3,808,824 | 1.84% | 주식 |
| MORGAN STANLEY | $14,802,946 | 3,474,870 | 1.68% | 주식 |
| BRAIDWELL LP | $14,732,908 | 3,458,429 | 1.67% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12,789,240 | 3,002,169 | 1.45% | 주식 |
| NORTHERN TRUST CORP | $12,299,856 | 2,887,290 | 1.39% | 주식 |
| UBS Group AG | $12,295,344 | 2,886,231 | 1.39% | 주식 |
| TWO SIGMA INVESTMENTS, LP | $11,475,213 | 2,693,712 | 1.30% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11,070,577 | 2,598,727 | 1.25% | 주식 |
| BANK OF AMERICA CORP /DE/ | $10,074,356 | 2,364,872 | 1.14% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $9,358,279 | 2,196,779 | 1.06% | 주식 |
| GOLDMAN SACHS GROUP INC | $9,178,165 | 2,154,499 | 1.04% | 주식 |
| WELLS FARGO & COMPANY/MN | $6,289,519 | 1,476,413 | 0.71% | 주식 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5,030,221 | 1,180,803 | 0.57% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $4,661,185 | 1,094,192 | 0.53% | 주식 |
| Caption Management, LLC | $4,260,000 | 1,000,000 | 0.48% | 풋 옵션 |
| Bank of New York Mellon Corp | $3,827,454 | 898,463 | 0.43% | 주식 |
| CITADEL ADVISORS LLC | $3,818,068 | 896,260 | 0.43% | 주식 |
| J. Goldman & Co LP | $3,478,669 | 816,589 | 0.39% | 주식 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $3,019,973 | 1,232,642 | 0.34% | 주식 |
| SCOPIA CAPITAL MANAGEMENT LP | $2,960,534 | 694,961 | 0.34% | 주식 |
| Balyasny Asset Management L.P. | $2,914,296 | 684,107 | 0.33% | 주식 |
| TWO SIGMA ADVISERS, LP | $2,897,166 | 510,964 | 0.33% | 주식 |
| VICTORY CAPITAL MANAGEMENT INC | $2,771,407 | 650,565 | 0.31% | 주식 |
| Nuveen, LLC | $2,708,218 | 635,732 | 0.31% | 주식 |
| Swiss National Bank | $2,502,324 | 587,400 | 0.28% | 주식 |
| STATE OF WISCONSIN INVESTMENT BOARD | $2,177,052 | 511,045 | 0.25% | 주식 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $2,106,540 | 494,493 | 0.24% | 주식 |
| 1492 Capital Management LLC | $2,052,136 | 481,722 | 0.23% | 주식 |
| Mariner, LLC | $2,020,189 | 474,236 | 0.23% | 주식 |
| MILLENNIUM MANAGEMENT LLC | $1,836,597 | 431,126 | 0.21% | 주식 |
| Schonfeld Strategic Advisors LLC | $1,774,216 | 416,483 | 0.20% | 주식 |
| Squarepoint Ops LLC | $1,759,644 | 413,062 | 0.20% | 주식 |
| Jefferies Financial Group Inc. | $1,694,202 | 397,700 | 0.19% | 주식 |
| ExodusPoint Capital Management, LP | $1,666,261 | 391,141 | 0.19% | 주식 |
| JANE STREET GROUP, LLC | $1,658,418 | 389,300 | 0.19% | 콜 옵션 |
| PRINCIPAL FINANCIAL GROUP INC | $1,629,561 | 382,526 | 0.18% | 주식 |
| Man Group plc | $1,624,023 | 381,226 | 0.18% | 주식 |
| RHUMBLINE ADVISERS | $1,604,647 | 376,681 | 0.18% | 주식 |
행동주의자 및 5% 이상 소유자 2 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Alfred E. Mann, Alfred E. Mann Living Trust, Biomed Partners, LLC, Minimed Infusion, Inc., The Mann Group LLC ×2 제출 서류 | 2012년 7월 10일 | · | 최초 제출 | 수동적 투자 | SEC |
| 미공개 보고자, 미공개 보고자, 미공개 보고자, 미공개 보고자 | 2006년 1월 31일 | · | 최초 제출 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
회사 내부자 43 명의 내부자 · 27 임원 · 19 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Michael Castagna | Chief Executive Officer | 2026년 7월 15일 M | 2,433,779 | 1 | 4 | $-990,292 |
| Hakan Edstrom | President & CEO | 2015년 8월 27일 A | 1,114,340 | 0 | 0 | $0 |
| Christopher B Prentiss | Chief Financial Officer | 2026년 7월 15일 F | 318,668 | 0 | 0 | $0 |
| Juergen Martens | Corporate VP and COO | 2015년 8월 27일 A | 106,539 | 0 | 0 | $0 |
| Dominic Marasco | Pres, Endocrine Business Unit | 2026년 7월 15일 F | 343,398 | 0 | 0 | $0 |
| Sanjay R Singh | EVP Technical Operations | 2026년 7월 15일 M | 478,966 | 0 | 1 | $-94,448 |
| Stuart A Tross | Chief People & Workpl Officer | 2026년 7월 15일 M | 1,058,142 | 0 | 1 | $-297,548 |
| David Thomson | EVP Genl Counsel & Secretary | 2026년 7월 15일 M | 797,554 | 0 | 3 | $-930,755 |
| Ajay Ahuja | Chief Medical Officer | 2026년 3월 23일 A | 318,200 | 0 | 0 | $0 |
| Lauren M Sabella | EVP Operations | 2025년 7월 15일 F | 349,841 | 0 | 0 | $0 |
| Burkhard Blank | EVP Chief Medical Officer | 2025년 7월 15일 F | 460,791 | 0 | 0 | $0 |
| Joseph Kocinsky | Chief Technology Officer | 2022년 8월 27일 F | 745,233 | 0 | 0 | $0 |
| Alejandro Galindo | EVP Endocrine Business Unit | 2022년 2월 28일 A | 576,690 | 0 | 0 | $0 |
| Rosabel Realica Alinaya | VP, IR & Treasury | 2020년 8월 27일 A | 167,119 | 0 | 0 | $0 |
| David M Kendall | Chief Medical Officer | 2020년 7월 31일 P | 41,059 | 0 | 0 | $0 |
| Patrick Mccauley | Chief Commercial Officer | 2020년 2월 25일 A | 83,972 | 0 | 0 | $0 |
| Courtney Barton | Chief Compl & Privacy Officer | 2019년 7월 31일 P | 29,584 | 0 | 0 | $0 |
| Elizabeth Garrett Ingram | Chief Marketing Officer | 2019년 5월 14일 A | 43,012 | 0 | 0 | $0 |
| Raymond W. Urbanski | Corp VP, CMO | 2017년 8월 10일 S | 2,924 | 0 | 0 | $0 |
| Linda A Adreveno | Sr. VP, HR | 2016년 2월 18일 A | 92,200 | 0 | 0 | $0 |
| Alfred E Mann | Executive Chairman | 2015년 8월 22일 F | 1,005,990 | 0 | 0 | $0 |
| Diane Palumbo | Vice President, Human Resource | 2015년 2월 23일 F | 50,624 | 0 | 0 | $0 |
| Peter C Richardson | Chief Scientific Officer | 2012년 3월 3일 F | 133,611 | 0 | 0 | $0 |
| Richard L Anderson | Corporate VP | 2008년 11월 16일 F | 204,401 | 0 | 0 | $0 |
| John R. Riesenberger | VP & Chief Commercial Officer | 2008년 8월 13일 A | 14,650 | 0 | 0 | $0 |
| Dan Burns | VP & President, MKBP | 2006년 12월 8일 A | 14,800 | 0 | 0 | $0 |
| Wendell W Cheatham | VP, Medical & Reg Affairs | 2004년 8월 19일 A | 300 | 0 | 0 | $0 |
| Steven B. Binder | 이사 | 2026년 9월 25일 S | 713,258 | 0 | 5 | $-683,703 |
| Sabrina Kay | 이사 | 2026년 5월 20일 A | 265,600 | 0 | 0 | $0 |
| Jennifer Grancio | 이사 | 2026년 5월 20일 A | 244,815 | 0 | 0 | $0 |
| James Samuel Shannon | 이사 | 2026년 5월 20일 A | 64,635 | 0 | 0 | $0 |
| Michael A Friedman | 이사 | 2026년 5월 20일 A | 47,500 | 0 | 0 | $0 |
| Anthony C Hooper | 이사 | 2026년 5월 20일 A | 236,153 | 0 | 0 | $0 |
| Christine Mundkur | 이사 | 2026년 5월 20일 A | 254,493 | 0 | 0 | $0 |
| Ronald J Consiglio | 이사 | 2026년 5월 20일 A | 132,342 | 0 | 0 | $0 |
| Kent Kresa | 이사 | 2024년 5월 15일 A | 274,541 | 0 | 0 | $0 |
| Henry L Nordhoff | 이사 | 2019년 5월 14일 A | 103,426 | 0 | 0 | $0 |
| David Maccallum | 이사 | 2018년 5월 16일 A | 114,790 | 0 | 0 | $0 |
| Matthew J Pfeffer | 이사 | 2017년 8월 28일 F | 81,961 | 0 | 0 | $0 |
| Abraham E Cohen | 이사 | 2012년 8월 17일 S | 56,424 | 0 | 0 | $0 |
| Heather Hay Murren | 이사 | 2008년 8월 13일 A | 10,100 | 0 | 0 | $0 |
| Kathleen Connell | 이사 | 2006년 5월 25일 A | · | 0 | 0 | $0 |
| Llew Keltner | 이사 | 2006년 5월 25일 A | · | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
ETF 보유 현황 29 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| JSMD · Janus Detroit Street Trust | 0.62% | 1,678,187 NS | 2026년 7월 31일 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.52% | 29,891 SH | 2026년 10월 2일 | 일간 |
| JSML · Janus Detroit Street Trust | 0.49% | 450,643 NS | 2026년 7월 31일 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0.37% | 1,212,660 NS | 2026년 7월 31일 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.23% | 289,432 NS | 2026년 7월 31일 | N-PORT |
| FYX · First Trust Exchange-Traded AlphaDE… | 0.12% | 409,547 NS | 2026년 7월 31일 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.09% | 22,737 SH | 2026년 10월 2일 | 일간 |
| IBB · iShares Trust | 0.08% | 2,264,902 SH | 2026년 9월 11일 | 일간 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.08% | 330,117 SH | 2026년 8월 19일 | 일간 |
| IWO · iShares Trust | 0.08% | 2,877,921 SH | 2026년 9월 11일 | 일간 |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.07% | 109,855 NS | 2026년 7월 31일 | N-PORT |
| PWS · Pacer Funds Trust | 0.06% | 3,954 NS | 2026년 7월 31일 | N-PORT |
| ESML · iShares Trust | 0.05% | 333,357 SH | 2026년 9월 11일 | 일간 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.04% | 1,771,496 SH | 2026년 8월 19일 | 일간 |
| RSSL · Global X Funds | 0.04% | 147,059 NS | 2026년 7월 31일 | N-PORT |
| ISCG · iShares Trust | 0.04% | 96,772 SH | 2026년 9월 11일 | 일간 |
| IWM · iShares Trust | 0.04% | 7,845,946 SH | 2026년 9월 11일 | 일간 |
| VHT · VANGUARD WORLD FUND | 0.02% | 874,372 SH | 2026년 8월 19일 | 일간 |
| FHLC · FIDELITY COVINGTON TRUST | 0.02% | 139,696 NS | 2026년 7월 31일 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 3,543,398 SH | 2026년 8월 19일 | 일간 |
| WSML · iShares Trust | 0.01% | 16,637 SH | 2026년 9월 11일 | 일간 |
| TILT · FlexShares Trust | 0.00% | 23,700 NS | 2026년 7월 31일 | N-PORT |
| ITOT · iShares Trust | 0.00% | 465,405 SH | 2026년 9월 11일 | 일간 |
| IWV · iShares Trust | 0.00% | 84,120 SH | 2026년 9월 10일 | 일간 |
| DFAC · Dimensional ETF Trust | 0.00% | 58,407 NS | 2026년 7월 31일 | N-PORT |
| DFAS · Dimensional ETF Trust | 0.00% | 11,291 NS | 2026년 7월 31일 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 9,327,332 SH | 2026년 8월 19일 | 일간 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 26,184 SH | 2026년 8월 19일 | 일간 |
| ISCB · iShares Trust | · | 13,557 SH | 2026년 9월 11일 | 일간 |
MNKD 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
평점 · 14 명의 애널리스트
매수
중앙값 목표
$7.50
+97.4%
4 28.6%
적극 매수
8 57.1%
매수
2 14.3%
보유
0 0.0%
매도
0 0.0%
적극 매도
12개월 목표 주가
8 명의 애널리스트 · 2026-10-05평균 목표 $7.97 +109.7%
← 모든 목표가 하회
현재가 $3.80
저가$4.75
평균$7.97
고가$13.00
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
회계연도 기준, 각 회사의 마지막 회계연도 말 종가 기준 가격입니다.
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | · |
| ORIC | $806M | -5.6 | · | · | -36.5% | · |
| DMRA | · | · | 38.3% | -17981.1% | -167.0% | · |
| REPL | $633M | -2.3 | · | · | -146.2% | · |
| TRAX | · | · | · | · | · | · |
| BCAX | $953M | -6.7 | · | · | -33.0% | · |
| VOR | $506M | -0.2 | · | · | 83.4% | · |
| MGTX | $645M | -5.6 | 144.6% | -140.3% | 8062.2% | · |
| JANX | $833M | -7.5 | -5.5% | -1136.2% | -11.7% | · |
최신 뉴스 이 회사 관련 최근 헤드라인
Wells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”
Yahoo Finance · 3개월, 3주 전
MannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy
Yahoo Finance · 3개월, 4주 전
H.C. Wainwright and Wells Fargo Lift MannKind (MNKD) Price Targets
Yahoo Finance · 4개월, 3주 전
맨카인드 코퍼레이션(MNKD)이 로빈후드에서 구매할 인기 있는 펜니 주식 중 하나인가요?
Yahoo Finance · 6개월 전
트레이딩 시그널 진입 가격 및 위험/보상 비율을 포함한 최근 매수/매도 신호
현재 열린 신호가 없습니다 — 카드가 채워지지 않았으며, 이는 정직한 것입니다.
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
중요한 지표를 선택하세요. 상단의 전체 기본 정보에서 원하는 행 옆의 +를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
출처: SEC 10-Q 제출 8월 5, 2026